World Drug Discovery and Development: Menopausal Hot Flashes – Pipeline Review, H1 2012

• Publication date: March 2013
• Report size: 52 pages

This report provides data on the therapeutic development for Menopausal Hot Flashes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Hot Flashes. 'Menopausal Hot Flashes - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websit...

This report provides data on the therapeutic development for Menopausal Hot Flashes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Hot Flashes. 'Menopausal Hot Flashes - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Menopausal Hot Flashes.
- A review of the Menopausal Hot Flashes products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Menopausal Hot Flashes pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Menopausal Hot Flashes.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Menopausal Hot Flashes pipeline depth and focus of Menopausal Hot Flashes therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Therapy Industry

Table of Contents

Data table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global March kets Direct Report Coverage 6
Menopausal Hot Flashes Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Menopausal Hot Flashes 8
Menopausal Hot Flashes Therapeutics under Development by Firms 10
Menopausal Hot Flashes Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Menopausal Hot Flashes Therapeutics – Products under Development by Firms 14
Menopausal Hot Flashes Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Menopausal Hot Flashes Therapeutics Development 16
Depomed, Inc. 16
November en Pharmaceuticals, Inc. 17
Bionovo, Inc. 18
Radius Health, Inc. 19
DSM Nutritional Products AG 20
Pherin Pharmaceuticals, Inc. 21
Menopausal Hot Flashes – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Serada - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Mesafem - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RAD1901 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Menerba - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Acupuncture + Gabapentin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Pregabalin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Megestrol Acetate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Citalopram hydrobromide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Prometrium - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PH80-HF - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Gabapentin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Menopausal Hot Flashes Therapeutics – Drug Profile Updates 42
Menopausal Hot Flashes Therapeutics – Discontinued Products 47
Menopausal Hot Flashes Therapeutics - Dormant Products 48
Menopausal Hot Flashes – Product Development Milestones 49
Featured News & Press Releases 49
November 16, 2011: Bionovo To Begin Dosing In Menerba Phase III Clinical Trial For Menopausal Hot Flashes 49
October 26, 2011: Bionovo Initiates Menerba Phase III Clinical Trial For Menopausal Hot Flashes 49
October 13, 2011: Depomed Announces Top-Line Results From Serada Phase III Trial BREEZE 3 In Menopausal Hot Flashes 50
August 30, 2011: Bionovo Announces Positive Results From Tolerability Trial Of Menerba For Menopausal Hot Flashes 51
July 25, 2011: Bionovo Announces Successful Completion Of Animal Toxicology Studies For MF101 52
May 03, 2011: Pfizer Announces Results From Phase III Efficacy Sub-Study Of PRISTIQ 52
March 28, 2011: Bionovo Initiates Enrollment In Menerba Phase I 'Tolerability' Clinical Trial For Menopausal Hot Flushes 53
March 03, 2011: Depomed Completes Enrollment Of Breeze 3 Phase III Clinical Trial for Non-Hormonal Treatment in Menopausal Hot Flashes 54
February 10, 2011: Bionovo Announces 2011 Plan Of Action On MF101 55
February 02, 2011: DSM Nutritional Products's GeniVida Reduces Hot Flashes and Night Sweats In Postmenopausal Women 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables

List of Tables
Number of Products Under Development for Menopausal Hot Flashes, H1 2012 8
Products under Development for Menopausal Hot Flashes – Comparative Analysis, H1 2012 9
Number of Products under Development by Firms, H1 2012 10
Number of Products under Investigation by Universities/Institutes, H1 2012 11
Comparative Analysis by Late Stage Development, H1 2012 12
Comparative Analysis by Mid Clinical Stage Development, H1 2012 13
Products under Development by Firms, H1 2012 14
Products under Investigation by Universities/Institutes, H1 2012 15
Depomed, Inc., H1 2012 16
November en Pharmaceuticals, Inc., H1 2012 17
Bionovo, Inc., H1 2012 18
Radius Health, Inc., H1 2012 19
DSM Nutritional Products AG, H1 2012 20
Pherin Pharmaceuticals, Inc., H1 2012 21
Assessment by Monotherapy Products, H1 2012 22
Assessment by Combination Products, H1 2012 23
Assessment by Stage and Route of Administration, H1 2012 25
Assessment by Stage and Molecule Type, H1 2012 27
Menopausal Hot Flashes Therapeutics – Drug Profile Updates 42
Menopausal Hot Flashes Therapeutics – Discontinued Products 47
Menopausal Hot Flashes Therapeutics – Dormant Products 48

List of Figures

List of Figures
Number of Products under Development for Menopausal Hot Flashes, H1 2012 8
Products under Development for Menopausal Hot Flashes – Comparative Analysis, H1 2012 9
Products under Development by Firms, H1 2012 10
Products under Investigation by Universities/Institutes, H1 2012 11
Late Stage Products, H1 2012 12
Mid Clinical Stage Products, H1 2012 13
Assessment by Monotherapy Products, H1 2012 22
Assessment by Combination Products, H1 2012 23
Assessment by Route of Administration, H1 2012 24
Assessment by Stage and Route of Administration, H1 2012 25
Assessment by Molecule Type, H1 2012 26
Assessment by Stage and Molecule Type, H1 2012 27